EX-99.1 2 ex_813015.htm EXHIBIT 99.1 ex_813015.htm

Exhibit 99.1

 

tplogo.jpg

 

Turning Point Brands Announces First Quarter 2025 Results

 

Net Sales for Q1 2025 Increased 28.1% Year-Over-Year to $106.4 million

Modern Oral Net Sales for Q1 2025 of $22.3 million

Q1 2025 Adjusted EBITDA of $27.7 million, up 12.0% over prior year

Reaffirm our previously announced 2025 Adjusted EBITDA guidance of $108.0  113.0 million; increasing full-year consolidated nicotine pouch sales guidance to a range of $80.0  95.0 million, from $60.0  80.0 million

 

LOUISVILLE, KY May 7, 2025 Turning Point Brands, Inc. (“TPB” or “the Company”) (NYSE: TPB), a manufacturer, marketer and distributor of branded consumer products, including alternative smoking accessories and consumables with active ingredients, today announced financial results for the first quarter ended March 31, 2025.

 

Q1 2025 vs. Q1 2024 

 

 

Total consolidated net sales increased 28.1% to $106.4 million

 

o

Stoker’s Products net sales increased 62.7% 

 

o

Zig-Zag Products net sales increased 1.2% 

 

Gross profit increased 23.3% to $59.6 million 

 

Net income increased 19.8% to $14.4 million 

 

Adjusted EBITDA increased 12.0% to $27.7 million (see Schedule A for a reconciliation to net income) 

 

Adjusted net income increased 8.0% to $16.7 million (see Schedule B for a reconciliation to net income) 

 

Diluted EPS of $0.79 and Adjusted Diluted EPS of $0.91 compared to $0.63 and $0.80, respectively, in the same period one year ago (see Schedule B for a reconciliation to Diluted EPS)

 

Graham Purdy, President and CEO, commented, “We are pleased with our first quarter results. Modern Oral sales were $22.3 million, up nearly 10-times versus the prior year and nearly double the prior quarter. Stoker’s MST and looseleaf exceeded our expectations, and Zig-Zag was in line with our expectations.”

 

Zig-Zag Products Segment (44% of total net sales in the quarter) 

 

For the first quarter, Zig-Zag Products net sales increased 1.2% to $47.3 million.

 

For the quarter, the Zig-Zag Products segment gross profit decreased 7.2% from the prior year but was up 2.9% sequentially from Q4 2024 to $25.6 million. Gross margin declined 490 basis points from the prior year but was flat sequentially at 54.1%.

 

Stokers Products Segment (56% of total net sales in the quarter) 

 

For the first quarter, Stoker’s Products net sales increased 62.7% to $59.2 million, driven by strong growth in Modern Oral sales, low double-digit growth in MST and low single-digit growth in looseleaf. For the first quarter, total Stoker’s Products segment volume increased 55.1%, while price / product mix increased 7.6%.

 

 

 

 

For the quarter, Stoker’s Products segment gross profit increased 63.6% from the prior year, and 23.5% sequentially from Q4 2024 to $34.0 million. Gross margin increased 30 basis points from the prior year, but decreased 20 basis points sequentially to 57.5%.

 

Performance Measures in the First Quarter 

 

First quarter 2025 consolidated selling, general and administrative (“SG&A”) expenses were $36.4 million compared to $29.1 million in the first quarter of 2024 primarily driven by ALP-related SG&A that was not in the prior year period.

 

First quarter SG&A included the following notable items: 

 

 

$1.6 million of FDA PMTA-related expenses for modern oral products compared to $0.8 million in the prior year period; and

 

$0.2 million of transaction-related costs compared to $0.0 million in the prior year period.

 

 

Total gross debt as of March 31, 2025 was $300.0 million. Net debt (total gross debt less unrestricted cash) as of March 31, 2025 was $200.4 million. The Company ended the quarter with total liquidity of $161.8 million, comprised of $99.6 million in cash and $62.2 million of availability under its asset backed revolving credit facility.  

 

2025 Outlook 

 

The Company is increasing projected Modern Oral sales from $60.0 – 80.0 million to $80.0 – 95.0 million.

 

The Company is maintaining its previous expectation for full-year 2025 adjusted EBITDA of $108.0 – 113.0 million.

 

Earnings Conference Call

 

As previously disclosed, a conference call with the investment community to review TPB’s financial results has been scheduled for 9:30 a.m. Eastern on Wednesday, May 7, 2025. Investment community participants should dial in 10 minutes ahead of time using the toll-free number (800) 715-9871 (international participants should call (646) 307-1963) and follow the audio prompts after typing in the event ID: 6640134. A live listen-only webcast of the call will be available on the Events and Presentations section of the investor relations portion of the Company website (www.turningpointbrands.com). A replay of the webcast will be available on the site two hours following the call. 

 

 

2
Turning Point Brands, Inc. | www.turningpointbrands.com | [email protected] | 502.774.9238

 

 

Non-GAAP Financial Measures 

 

In addition to financial measures prepared in accordance with generally accepted accounting principles in the United States (GAAP), this press release includes certain non-GAAP financial measures including EBITDA, Adjusted EBITDA, Adjusted Net Income, Adjusted Diluted EPS and Adjusted Operating Income (Loss). A reconciliation of these non-GAAP financial measures accompanies this release.

 

About Turning Point Brands, Inc. 

 

Turning Point Brands (NYSE: TPB) is a manufacturer, marketer and distributor of branded consumer products including smoking accessories and consumables with active ingredients through its Zig-Zag®, Stoker’s®, FRE ®, and Alp Pouch ® brands. TPB’s products are available in more than 220,000 retail outlets in North America, and on sites such as www.zigzag.com. For the latest news and information about TPB and its brands, please visit www.turningpointbrands.com.

 

Forward-Looking Statements  

  

This press release contains forward-looking statements within the meaning of the federal securities laws. Forward-looking statements may generally be identified by the use of words such as "anticipate," "believe," "expect," "intend," "plan" and "will" or, in each case, their negative, or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. As a result, these statements are not guarantees of future performance and actual events may differ materially from those expressed in or suggested by the forward-looking statements. Any forward-looking statement made by TPB in this press release, its reports filed with the Securities and Exchange Commission (the “SEC”) and other public statements made from time-to-time speak only as of the date made. New risks and uncertainties come up from time to time, and it is impossible for TPB to predict or identify all such events or how they may affect it. TPB has no obligation, and does not intend, to update any forward-looking statements after the date hereof, except as required by federal securities laws. Factors that could cause these differences include, but are not limited to, those included in the Company’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other reports filed by the Company with the SEC. These statements constitute the Company’s cautionary statements under the Private Securities Litigation Reform Act of 1995.  

 

Investor Contacts 

 

Turning Point Brands, Inc. 

[email protected]

 

 

Financial Statements Follow on Subsequent Pages

 

3
Turning Point Brands, Inc. | www.turningpointbrands.com | [email protected] | 502.774.9238

 

Turning Point Brands, Inc.

Consolidated Statements of Income

(dollars in thousands except share data)

(unaudited)

 

   

Three Months Ended March 31,

 
   

2025

   

2024

 
                 

Net sales

  $ 106,436     $ 83,064  

Cost of sales

    46,826       34,710  

Gross profit

    59,610       48,354  

Selling, general, and administrative expenses

    36,421       29,084  

Operating income

    23,189       19,270  

Interest expense, net

    4,414       3,479  

Investment gain

    (291 )     (119 )

Loss on extinguishment of debt

    1,235       -  

Income from continuing operations before income taxes

    17,831       15,910  

Income tax expense

    2,040       3,729  

Income from continuing operations

    15,791       12,181  

Loss from discontinued operations, net of tax

    -       (2 )

Consolidated net income

    15,791       12,179  

Net income attributable to non-controlling interest

    1,396       169  

Net income attributable to Turning Point Brands, Inc.

  $ 14,395     $ 12,010  
                 

Basic income per common share:

               

Continuing operations

  $ 0.81     $ 0.68  

Discontinued operations

    -       -  

Net income attributable to Turning Point Brands, Inc.

  $ 0.81     $ 0.68  

Diluted income per common share:

               

Continuing operations

  $ 0.79     $ 0.63  

Discontinued operations

    -       -  

Net income attributable to Turning Point Brands, Inc.

  $ 0.79     $ 0.63  

Weighted average common shares outstanding:

               

Basic

    17,795,243       17,654,684  

Diluted

    18,249,306       20,170,314  

 

4
Turning Point Brands, Inc. | www.turningpointbrands.com | [email protected] | 502.774.9238

 

Turning Point Brands, Inc.

Consolidated Balance Sheets

(dollars in thousands except share data)

 

   

(unaudited)

         
   

March 31,

   

December 31,

 
   

2025

   

2024

 
ASSETS                

Current assets:

               

Cash

  $ 99,640     $ 46,158  

Accounts receivable, net of allowances of $75 in 2025 and $66 in 2024

    14,861       9,624  

Inventories, net

    104,440       96,253  

Current assets held for sale

    -       11,470  

Other current assets

    40,072       34,700  

Total current assets

    259,013       198,205  

Property, plant, and equipment, net

    27,659       26,337  

Deferred tax assets, net

    -       995  

Right of use assets

    10,788       11,610  

Deferred financing costs, net

    1,662       1,823  

Goodwill

    135,780       135,932  

Other intangible assets, net

    64,939       65,254  

Master Settlement Agreement (MSA) escrow deposits

    29,317       28,676  

Noncurrent assets held for sale

    -       3,859  

Other assets

    35,394       20,662  

Total assets

  $ 564,552     $ 493,353  
                 

LIABILITIES AND STOCKHOLDERS' EQUITY

               

Current liabilities:

               

Accounts payable

  $ 27,007     $ 11,675  

Accrued liabilities

    31,596       31,096  

Current liabilities held for sale

    -       2,049  

Total current liabilities

    58,603       44,820  

Deferred tax liabilities, net

    885       -  

Notes payable and long-term debt

    293,062       248,604  

Lease liabilities

    8,565       9,549  

Total liabilities

  $ 361,115     $ 302,973  
                 

Commitments and contingencies

               
                 

Stockholders' equity:

               

Preferred stock, $0.01 par value; authorized shares 40,000,000; issued and outstanding shares -0-

    -       -  

Common stock, voting, $0.01 par value; authorized shares, 190,000,000; 20,366,910 issued shares and 17,895,505 outstanding shares at March 31, 2025, and 20,200,886 issued shares and 17,729,481 outstanding shares at December 31, 2024

    204       202  

Common stock, nonvoting, $0.01 par value; authorized shares, 10,000,000; issued and outstanding shares -0-

    -       -  

Additional paid-in capital

    124,811       126,662  

Cost of repurchased common stock (2,471,405 shares at March 31, 2025 and December 31, 2024)

    (83,144 )     (83,144 )

Accumulated other comprehensive loss

    (2,363 )     (2,903 )

Accumulated earnings

    160,182       147,164  

Non-controlling interest

    3,747       2,399  

Total stockholders' equity

    203,437       190,380  

Total liabilities and stockholders' equity

  $ 564,552     $ 493,353  

 

5
Turning Point Brands, Inc. | www.turningpointbrands.com | [email protected] | 502.774.9238

 

Turning Point Brands, Inc.

Consolidated Statements of Cash Flows

(dollars in thousands)

(unaudited)

 

 

   

Three Months Ended March 31,

 
   

2025

   

2024

 

Cash flows from operating activities:

               

Consolidated net income

  $ 15,791     $ 12,179  

Loss from discontinued operations, net of tax

    -       2  

Adjustments to reconcile net income to net cash provided by operating activities:

               

Loss on extinguishment of debt

    1,235       -  

Loss on sale of property, plant, and equipment

    40       1  

Depreciation and other amortization expense

    1,309       848  

Amortization of other intangible assets

    307       305  

Amortization of deferred financing costs

    448       696  

Deferred income tax expense

    1,716       114  

Stock compensation expense

    1,664       2,062  

Noncash lease income

    (380 )     (42 )

Loss on MSA investments

    -       6  

Changes in operating assets and liabilities:

               

Accounts receivable

    (5,539 )     1,846  

Inventories

    (8,310 )     (7,488 )

Other current assets

    (5,399 )     1,050  

Other assets

    (4,201 )     (270 )

Accounts payable

    15,433       10,800  

Accrued liabilities and other

    512       (2,933 )

Operating cash flows from continuing operations

    14,626       19,176  

Operating cash flows from discontinued operations

    -       3,463  

Net cash provided by operating activities

  $ 14,626     $ 22,639  
                 

Cash flows from investing activities:

               

Capital expenditures

  $ (2,185 )   $ (366 )

Purchases of investments

    (714 )     (7,119 )

Proceeds from sale of investments

    500       -  

Purchases of non-marketable equity investments

    -       (500 )

MSA escrow deposits, net

    (48 )     (1 )

Investing cash flows from continuing operations

    (2,447 )     (7,986 )

Investing cash flows from discontinued operations

    -       -  

Net cash used in investing activities

  $ (2,447 )   $ (7,986 )
                 

Cash flows from financing activities:

               

Redemption of 2026 Notes

  $ (250,000 )   $ -  

Proceeds from 2032 Notes

    300,000       -  

Payment of dividends

    (1,385 )     (1,149 )

Payment of financing costs

    (6,582 )     -  

Exercise of options

    973       3  

Redemption of options

    (33 )     -  

Redemption of restricted stock units

    (1,828 )     (136 )

Redemption of performance based restricted stock units

    (2,625 )     (1,212 )

Common stock repurchased

    -       (2,079 )

Financing cash flows from continuing operations

    38,520       (4,573 )

Financing cash flows from discontinued operations

    -       -  

Net cash provided by (used in) financing activities

  $ 38,520     $ (4,573 )
                 

Net increase in cash

  $ 50,699     $ 10,080  

Effect of foreign currency translation on cash

  $ (48 )   $ (58 )
                 

Cash, beginning of period:

               

Unrestricted

  $ 48,941     $ 117,886  

Restricted

    1,961       4,929  

Total cash at beginning of period

  $ 50,902     $ 122,815  
                 

Cash, end of period:

               

Unrestricted

  $ 99,640     $ 130,903  

Restricted

    1,913       1,934  

Total cash at end of period

  $ 101,553     $ 132,837  

 

6
Turning Point Brands, Inc. | www.turningpointbrands.com | [email protected] | 502.774.9238

 

 

Non-GAAP Financial Measures

 

To supplement our financial information presented in accordance with generally accepted accounting principles in the United States, or U.S. GAAP, we use non-U.S. GAAP financial measures, including EBITDA, Adjusted EBITDA, Adjusted Net Income, Adjusted Diluted EPS, and Adjusted Operating Income . We believe Adjusted EBITDA provides useful information to management and investors regarding certain financial and business trends relating to our financial condition and results of operations. Adjusted EBITDA, Adjusted Net Income, Adjusted Diluted EPS, and Adjusted Operating Income are used by management to compare our performance to that of prior periods for trend analyses and planning purposes and are presented to our board of directors. We believe that EBITDA, Adjusted EBITDA, Adjusted Net Income, Adjusted Diluted EPS, and Adjusted Operating Income are appropriate measures of operating performance because they eliminate the impact of expenses that do not relate to business performance.

 

We define “EBITDA” as net income before interest expense, gain (loss) on extinguishment of debt, income tax expense, depreciation, amortization. We define “Adjusted EBITDA” as net income before interest expense, gain (loss) on extinguishment of debt, income tax expense, depreciation, amortization, other non-cash items and other items that we do not consider ordinary course in our evaluation of ongoing operating performance. We define “Adjusted Net Income” as net income excluding items that we do not consider ordinary course in our evaluation of ongoing operating performance. We define “Adjusted Diluted EPS” as diluted earnings per share excluding items that we do not consider ordinary course in our evaluation of ongoing operating performance. We define “Adjusted Operating Income” as operating income excluding other non-cash items and other items that we do not consider ordinary course in our evaluation of ongoing operating performance.

 

Non-U.S. GAAP measures should not be considered a substitute for, or superior to, financial measures calculated in accordance with U.S. GAAP. EBITDA, Adjusted Net Income, Adjusted EBITDA, Adjusted Diluted EPS, and Adjusted Operating Income exclude significant expenses that are required by U.S. GAAP to be recorded in our financial statements and is subject to inherent limitations. In addition, other companies in our industry may calculate this non-U.S. GAAP measure differently than we do or may not calculate it at all, limiting its usefulness as a comparative measure.

 

In accordance with SEC rules, we have provided, in the supplemental information attached, a reconciliation of the non-GAAP measures to the next directly comparable GAAP measures.

 

7
Turning Point Brands, Inc. | www.turningpointbrands.com | [email protected] | 502.774.9238

 

Schedule A

 
 
 

Turning Point Brands, Inc.

Reconciliation of GAAP Net Income to Adjusted EBITDA

(dollars in thousands)

(unaudited)

 

   

Three Months Ended

 
   

March 31,

 
   

2025

   

2024

 

Net income attributable to Turning Point Brands, Inc.

  $ 14,395     $ 12,010  

Add:

               

Interest expense, net

    4,401       3,479  

Loss on extinguishment of debt

    1,235       -  

Income tax expense

    2,040       3,729  

Depreciation expense

    828       741  

Amortization expense

    822       412  

EBITDA

  $ 23,721     $ 20,371  

Components of Adjusted EBITDA

               

Corporate restructuring (a)

    -       1,261  

ERP/CRM (b)

    211       138  

Stock based compensation (c)

    1,664       2,062  

Transactional expenses and strategic initiatives (d)

    176       30  

FDA PMTA (e)

    1,591       841  
Mark-to-market loss on Canadian inter-company note (f)     315       -  

Adjusted EBITDA

  $ 27,678     $ 24,703  

 

(a)

Represents costs associated with corporate restructuring, including severance and early retirement.

(b)

Represents cost associated with scoping and mobilization of new ERP and CRM systems and cost of duplicative ERP licenses.

(c)

Represents non-cash stock options, restricted stock, PRSUs, etc.

(d)

Represents the fees incurred for transaction expenses.

(e)

Represents costs associated with applications related to FDA premarket tobacco product application (“PMTA”). The PMTA regime requires the Company to submit an application to the FDA to receive marketing authorization to continue to sell certain of its product lines with continued sales permitted during the pendency of the applications. The application is a onetime resource-intensive process for each covered product line; however, due to the nature of the implementation process for those product lines already in the market, applications can take multiple years to complete rather than the typical one-time submission. The Company currently has only two product lines currently subject to the PMTA process, having utilized other regulatory pathway options available for our other product lines. The Company does not expect to submit additional PMTA applications for any new product lines after the submission for the remaining two are complete.

(f)

Represents a mark-to-market loss attributable to foreign exchange fluctuation.

 

8
Turning Point Brands, Inc. | www.turningpointbrands.com | [email protected] | 502.774.9238

 

Schedule B

 

Turning Point Brands

Reconciliation of GAAP Net Income to Adjusted Net Income and Diluted EPS to Adjusted Diluted EPS

(dollars in thousands except share data)

(unaudited)

 

   

Three Months Ended

   

Three Months Ended

 
   

March 31, 2025

   

March 31, 2024

 
                                                                   
   

Income from continuing operations before income taxes

   

Income tax expense (i)

   

Net income attributable to non-controlling interest

   

Net Income

   

Diluted EPS

   

Income from continuing operations before income taxes

   

Income tax expense (i)

   

Loss from discontinued operations, net of tax (j)

   

Net income attributable to non-controlling interest

   

Net Income

   

Diluted EPS

 

GAAP Net Income and Diluted EPS

  $ 17,831     $ 2,040     $ 1,396     $ 14,395     $ 0.79     $ 15,910     $ 3,729     $ 2     $ 169     $ 12,010     $ 0.63  

Loss on discontinued operations (a)

    -       -       -       -       -       -       -       (3 )     -       3       0.00  

Loss on extinguishment of debt (b)

    1,235       141       -       1,094       0.06       -       -       -       -       -       -  

Corporate restructuring (c)

    -       -       -       -       -       1,261       295       -       -       966       0.05  

ERP/CRM (d)

    211       24       -       187       0.01       138       32       -       -       106       0.01  

Stock options, restricted stock, and incentives expense (e)

    1,664       190       -       1,474       0.08       2,062       483       -       -       1,579       0.08  

Transactional expenses and strategic initiatives (f)

    176       20       -       156       0.01       30       7       -       -       23       0.00  

FDA PMTA (g)

    1,591       182       -       1,409       0.08       841       197       -       -       644       0.03  

Mark-to-market loss on Canadian inter-company note (h)

    315       36       -       279       0.02       -       -                                  

Tax benefit (i)

    -       2,329       -       (2,329 )     (0.13 )     -       (93 )     -       -       93       0.00  

Adjusted Net Income and Adjusted Diluted EPS

  $ 23,023     $ 4,963     $ 1,396     $ 16,664     $ 0.91     $ 20,242     $ 4,650     $ (1 )   $ 169     $ 15,424     $ 0.80  

 

   

Totals may not foot due to rounding

   
   

(a)  

Represents loss on discontinued operations.

(b)  

Represents loss on extinguishment of debt as a result of the redemption of the 2026 Notes.

(c) 

Represents costs associated with corporate restructuring, including severance and early retirement.

(d) 

Represents cost associated with scoping and mobilization of new ERP and CRM systems and cost of duplicative ERP licenses.

(e)  

Represents non-cash stock options, restricted stock, PRSUs, etc.

(f)  

Represents the fees incurred for transaction expenses.

(g) 

Represents costs associated with applications related to FDA premarket tobacco product application ("PMTA").  The PMTA regime requires the Company to submit an application to the FDA to receive marketing authorization to continue to sell certain of its product lines with continued sales permitted during the pendency of the applications. The application is a onetime resource-intensive process for each covered product line; however, due to the nature of the implementation process for those product lines already in the market, applications can take multiple years to complete rather than the typical one-time submission. The Company currently has only two product lines currently subject to the PMTA process, having utilized other regulatory pathway options available for our other product lines. The Company does not expect to submit additional PMTA applications for any new product lines after the submission for the remaining two are complete.

(h) 

Represents adjustment from quarterly tax rate to quarterly projected tax rate of 21% in 2025 and 23% in 2024.

(i) 

Income tax expense calculated using the effective tax rate for the quarter of 11.4% in 2025 and 23.4% in 2024.

(j)

Tax allocation for discontinued operations excluded from adjusted net income.

 

9
Turning Point Brands, Inc. | www.turningpointbrands.com | [email protected] | 502.774.9238

 

Schedule C

 

Turning Point Brands, Inc.

Reconciliation of GAAP Operating Income to Adjusted Operating Income 

(dollars in thousands)

(unaudited)

 

   

Consolidated

   

Zig-Zag Products

   

Stoker's Products

 
   

1st Quarter

   

1st Quarter

   

1st Quarter

   

1st Quarter

   

1st Quarter

   

1st Quarter

 
   

2025

   

2024

   

2025

   

2024

   

2025

   

2024

 
                                                 

Net sales

  $ 106,436     $ 83,064     $ 47,265     $ 46,697     $ 59,171     $ 36,367  
                                                 

Gross profit

  $ 59,610     $ 48,354     $ 25,565     $ 27,539     $ 34,045     $ 20,815  
                                                 

Operating income

  $ 23,189     $ 19,270     $ 16,930     $ 18,000     $ 24,134     $ 15,396  

Adjustments:

                                               

Corporate restructuring

    -       1,261       -       -       -       -  

ERP/CRM

    211       138       -       -       -       -  

Transactional expenses and strategic initiatives

    176       30       -       -       -       -  

FDA PMTA

    1,591       841      

-

      -       -       -  

Mark-to-market loss on Canadian inter-company note

    315       -       -       -       -       -  

Adjusted operating income

  $ 25,482     $ 21,540     $ 16,930     $ 18,000     $ 24,134     $ 15,396  

 

10
Turning Point Brands, Inc. | www.turningpointbrands.com | [email protected] | 502.774.9238